Physician profile
Abdul Aleem
NPI 1508232711
$1,152.70
in general payments reported to CMS, 2019-2025
11 companies · $527 in 2025
The $527 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2024: $500 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Education: $25.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.10 |
| Education | $25.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.15 | 2024-2025 | |
| Lumendi LLC | $224.48 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $171.55 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $105.60 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $89.12 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $67.41 | 2024-2025 | Tremfya, Stelara |
| Celgene Corporation | $58.03 | 2024 | Zeposia |
| Celltrion USA INC. | $50.84 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $23.41 | 2025 | Rezdiffra |
| Qol Medical, LLC | $18.53 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $17.58 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Aleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.